Levofloxacine Fresenius Kabi (Levofloxacin Hemihydrate)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes that control DNA supercoiling and replication. By binding to these targets, the drug prevents DNA synthesis and transcription, leading to bacterial cell death. This mechanism provides broad‑spectrum, concentration‑dependent bactericidal activity against many Gram‑positive and Gram‑negative organisms.

The specific dose and duration of therapy are determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local resistance patterns. Healthcare professionals should follow institutional guidelines and product labeling when selecting the appropriate regimen.

The safety of levofloxacin in pregnancy and lactation has not been established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians are advised to discuss alternatives and consider fetal monitoring when prescribing to pregnant or nursing patients.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Levofloxacin is a third‑generation fluoroquinolone with enhanced activity against Gram‑positive organisms compared with earlier agents like ciprofloxacin. It offers once‑daily dosing for many indications and has a favorable pharmacokinetic profile, but shares class‑related risks such as tendon toxicity and QT prolongation, which must be weighed against alternative antibiotics.

The product should be stored at ambient temperature below 25 °C, protected from moisture and direct light. Keep the vial in its original packaging until use and avoid freezing. If reconstituted, follow the manufacturer’s guidance on stability and discard any unused solution after the specified period.

Levofloxacine Fresenius Kabi is supplied as an intravenous solution for infusion. It is administered by a qualified healthcare professional through a peripheral or central line, typically over 30–60 minutes depending on the dose and clinical protocol. Infusion rates and dilution volumes should follow the product’s prescribing information.

Serious adverse events include tendon rupture (especially the Achilles tendon), QT interval prolongation leading to arrhythmias, severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome, and Clostridioides difficile‑associated colitis. Patients should be monitored closely for musculoskeletal pain, cardiac symptoms, or any signs of allergic reaction during treatment.

Levofloxacine Fresenius Kabi is contraindicated in patients with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the formulation. Caution is also advised for individuals with a history of tendon disorders, prolonged QT interval, or severe renal impairment where dose adjustment is required.